PREDNISONE Drug Patent Profile

When do Prednisone patents expire, and what generic alternatives are available?

Prednisone is a drug marketed by Hikma, Xttrium Labs Inc, Actavis Labs Fl Inc, Dr Reddys, Aiping Pharm Inc, Am Therap, Amneal, Amneal Pharms Ny, Aurobindo Pharma Ltd, Bundy, Chartwell Molecular, Chartwell Rx, Contract Pharmacal, Duramed Pharms Barr, Elkins Sinn, Everylife, Ferrante, Geneyork Pharms, Halsey, Heather, Hikma Pharms, Impax Labs, Inwood Labs, Ivax Sub Teva Pharms, Jubilant Cadista, Kv Pharm, Lederle, Marshall Pharma, Mutual Pharm, Mylan, Novitium Pharma, Nylos, Panray, Ph Health, Pharmavite, Phoenix Labs Ny, Pointview Hldings, Purepac Pharm, Pvt Form, Rexall, Rising, Roxane, Scherer Labs, Sperti, Strides Pharma, Sun Pharm Industries, Superpharm, Teva, UDL, Upsher Smith, Valeant Pharm Intl, Vangard, Vitarine, Watson Labs, and Whiteworth Town Plsn. and is included in one hundred and ten NDAs.

The generic ingredient in PREDNISONE is prednisone. There are sixteen drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the prednisone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Prednisone

A generic version of PREDNISONE was approved as prednisone by WATSON LABS on December 31^st, 1969.

Summary for PREDNISONE

US Patents:	0
Applicants:	55
NDAs:	110
Finished Product Suppliers / Packagers:	49
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2,195
Patent Applications:	4,458
Drug Prices:	Drug price information for PREDNISONE
Drug Sales Revenues:	Drug sales revenues for PREDNISONE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PREDNISONE
DailyMed Link:	PREDNISONE at DailyMed

See drug prices for PREDNISONE

See drug sales revenues for PREDNISONE

Recent Clinical Trials for PREDNISONE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sunnybrook Health Sciences Centre	PHASE4
The Physicians' Services Incorporated Foundation	PHASE4
Children's Oncology Group	PHASE2

See all PREDNISONE clinical trials

Pharmacology for PREDNISONE

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Medical Subject Heading (MeSH) Categories for PREDNISONE

Anti-Inflammatory Agents

Antineoplastic Agents, Hormonal

Glucocorticoids

Anatomical Therapeutic Chemical (ATC) Classes for PREDNISONE

A07EA	Corticosteroids acting locally
A07E	INTESTINAL ANTIINFLAMMATORY AGENTS
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A	Alimentary tract and metabolism

H02AB	Glucocorticoids
H02A	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
H02	CORTICOSTEROIDS FOR SYSTEMIC USE
H	Systemic hormonal preparations, excluding sex hormones and insulins

Paragraph IV (Patent) Challenges for PREDNISONE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RAYOS	Delayed-release Tablets	prednisone	5 mg	202020	1	2012-11-26

US Patents and Regulatory Information for PREDNISONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Jubilant Cadista	PREDNISONE	prednisone	TABLET;ORAL	040362-003	Jun 29, 2005	AB	RX	No	No
Pointview Hldings	PREDNISONE	prednisone	TABLET;ORAL	212629-001	Dec 5, 2023	AB	RX	No	No
Geneyork Pharms	PREDNISONE	prednisone	TABLET;ORAL	210525-004	Dec 7, 2018		DISCN	No	No
Duramed Pharms Barr	PREDNISONE	prednisone	TABLET;ORAL	088396-001	Oct 4, 1983		DISCN	No	No
Novitium Pharma	PREDNISONE	prednisone	TABLET;ORAL	211575-003	Nov 15, 2019	AB	RX	No	No

Market Dynamics and Financial Trajectory for Prednisone

Last updated: February 16, 2026

Prednisone, a corticosteroid used for its anti-inflammatory and immunosuppressive properties, has sustained demand across multiple therapeutic areas, including autoimmune diseases, allergic conditions, and certain cancers. Its market environment is shaped by patent status, generic availability, evolving clinical guidelines, and regulatory policies.

---

Current Market Landscape

Global Market Size and Growth
The global prednisone market was valued at approximately $1.2 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 3.2% through 2027, reaching nearly $1.5 billion. The growth is driven by expanded use in autoimmune conditions such as rheumatoid arthritis, asthma, and other inflammatory diseases.

Geographic Distribution
North America accounts for 45% of sales, owing to established healthcare infrastructure and the prevalence of autoimmune disorders. Europe holds around 30%, with growth influenced by aging demographics. Asia-Pacific, with a CAGR of 4.5%, exhibits increasing demand due to expanding healthcare access.

Market Segments

• Branded formulations: Comprise less than 10% of sales; primarily used where specific clinical preference persists.
• Generic versions: Constitute over 90%, dominant due to patent expiration (primarily post-2010).

---

Patent Status and Generics Influence

Patent Expiry Timeline
Prednisone’s primary patent expired by 2010 in the U.S. and EU, leading to widespread generic manufacturing. This transition has significantly depressed branded prices and concentrated market share among generics.

Impact of Generics
The post-patent environment has reduced manufacturing barriers, leading to increased competition and price erosion—downward pressure has reduced unit prices by approximately 50% between 2010 and 2022. Innovations, such as controlled-release formulations, remain patent-protected but account for a small market segment.

---

Pricing and Reimbursement Factors

Pricing Trends
Average wholesale prices (AWP) for prednisone tablets decreased from ~$0.20 per 5mg dose in 2010 to ~$0.10 by 2022. Variability exists regionally, driven by reimbursement policies, pharmacy benefit management, and healthcare system structures.

Reimbursement Policies
In the U.S., Medicaid and Medicare Part D coverage favor generics, limiting revenue opportunities for branded versions. In Europe, national healthcare systems negotiate drug prices, which constrains revenue growth.

---

Regulatory Environment and Clinical Guidelines

Regulatory Approvals
Manufacturers must adhere to stringent quality standards mandated by FDA and EMA. Regulatory approval for new formulations is restricted due to the drug's age. However, orphan indication approvals can create new revenue streams.

Clinical Relevance and Usage Trends
Guidelines favor corticosteroids for specific indications but emphasize minimizing long-term use due to adverse effects. Use has plateaued in some therapeutic areas, limiting new sales opportunities but maintaining stable demand for existing formulations.

---

Competitive Landscape

Major Players

• Teva Pharmaceuticals
• Sandoz (Novartis)
• Mylan (now part of Viatris)
• Lupin Pharmaceuticals

Market Shares
Generics account for over 85% of sales. Teva and Sandoz lead with approximately 35% combined market share. Brand manufacturers largely exited or reduced presence post-patent expiry.

Market Entry Barriers
High manufacturing quality standards and regulatory approvals favor existing generic manufacturers. Strategic alliances with pharmacies and upstream suppliers influence market positioning.

---

Forecasted Financial Trajectory

Revenue Projections
Demand stability in chronic conditions and expanding use for short-term treatment sustain revenue levels. However, intensified price competition forecasts a decline in unit prices, constraining growth.

Profitability Outlook
Manufacturers with cost-efficient production and limited dependency on patent-exclusive formulations will experience margins ranging from 10-15%, with potential for margin compression owing to price competition.

Risks and Opportunities

• Risks: Price erosion, regulatory tightening, shifts toward alternative therapies.
• Opportunities: Development of unique formulations (e.g., liquid or injectable) for niche indications, potential orphan drug status, regional expansion, and biosimilars.

---

Key Takeaways

• Prednisone's market has transitioned primarily to generics, with limited opportunities for branded revenue growth.
• Market size is steady, around $1.2 billion globally, with slow CAGR of about 3.2%, driven by autoimmune and inflammatory disease prevalence.
• Price erosion remains significant, with unit prices cut by half post-expiry of patents.
• Regional variations influence revenue, with North America leading and Asia-Pacific showing higher growth potential.
• Future revenue streams lie in niche formulations, regional market expansion, and regulatory-driven indications.

---

FAQs

1. How does patent expiration affect prednisone's market?
Patent expiry in 2010 allowed multiple manufacturers to produce generics, increasing competition and reducing prices, which limits branded market share and revenue.

2. What factors influence prednisolone prices worldwide?
Regulatory policies, healthcare reimbursement systems, and manufacturing costs influence prices, with aggressive price negotiations in Europe and U.S. favoring low-cost generics.

3. Are there new formulations or indications for prednisone?
Limited new formulations are in development due to the drug's age. Some manufacturers explore controlled-release versions or injectable forms for specific conditions.

4. What is the outlook for branded prednisone sales?
Branded sales are declining; future growth hinges on orphan indications, specialty formulations, or regional niche markets.

5. How do regulatory changes impact the prednisone market?
Regulatory agencies focus on quality, safety, and patent protections. Stricter rules could delay or restrict new formulations, but they have minimal impact on existing generics.

---

References

1. MarketWatch, "Prednisone Market Size, Share & Trends," 2022.
2. IQVIA, "Global Pharmaceutical Market Report," 2022.
3. U.S. Food and Drug Administration, "ANDA Approvals," 2022.
4. European Medicines Agency, "Drug Marketing Authorizations," 2022.
5. GlobalData, "Corticosteroids Market Analysis," 2022.